Cervical Cancer Screening and Colposcopy

Cervical cancer screening represents one of the most successful cancer prevention programs in modern medicine, utilizing cytologic and virologic testing to detect precancerous lesions before progression to invasive malignancy. Cervical cancer, predominantly caused by high-risk human papillomavirus (HPV) infection, remains the fourth most common cancer worldwide and the leading cause of cancer-related death in women in low-resource countries. In the United States, the incidence has declined dramatically from 14.2 per 100,000 in 1955 to approximately 7-8 per 100,000 currently due to widespread screening implementation. The disease predominantly affects women between ages 35-55, with peak incidence in the fifth and sixth decades of life. Understanding cervical cancer pathogenesis, screening methodologies, and colposcopic evaluation is essential for preventive medicine and for USMLE Step 2 CK success, as screening abnormalities and colposcopy interpretation represent high-frequency clinical scenarios. Effective screening has reduced cervical cancer mortality by 70% in screened populations compared to unscreened controls.

The transformation of normal cervical epithelium to invasive carcinoma represents a stepwise accumulation of molecular abnormalities driven primarily by persistent high-risk HPV infection. This process occurs over 10-20 years, providing an exceptional opportunity for screening intervention. High-risk HPV types (particularly HPV-16 and HPV-18, accounting for approximately 70% of cervical cancers) express viral oncoproteins E6 and E7 that fundamentally disrupt normal cell cycle control. The E7 protein binds to and inactivates the retinoblastoma (Rb) protein, which normally acts as a checkpoint control mechanism preventing progression from G1 to S phase of the cell cycle. Viral E7-mediated Rb degradation releases E2F transcription factors, constitutively driving S-phase genes and forcing cells into uncontrolled proliferation. Simultaneously, E6 protein targets the p53 tumor suppressor through ubiquitin-mediated proteasomal degradation, eliminating p53-dependent apoptosis and DNA damage response mechanisms. This dual inactivation of Rb and p53 pathways creates a permissive environment for uncontrolled cellular proliferation that would normally trigger senescence or apoptosis in response to oncogenic stress.

High-risk HPV initiates infection at the transformation zone of the cervix, where columnar endocervical epithelium meets stratified squamous ectocervical tissue—an area of active metaplasia and cellular vulnerability. The virus preferentially infects immature metaplastic cells and parabasal cells with access to basal epithelial stem cells. Following initial infection, HPV DNA exists episomally (as circular, non-integrated DNA) in the cytoplasm during early productive infection stages. However, in a subset of persistently infected cells, particularly those under selective pressure from immune evasion, random integration of HPV DNA into the host genome occurs. This integration event is typically associated with disruption of the viral E1/E2 genes, which normally function as negative regulators of E6/E7 expression. Loss of E2-mediated repression results in dramatically increased and uncontrolled E6/E7 expression, further driving malignant transformation. Integrated HPV genomes show remarkable genomic instability, with frequent deletions, rearrangements, and amplifications that accumulate additional oncogenic mutations.

The histologic and molecular progression from normal epithelium to invasive carcinoma follows a recognized continuum: normal cervix → CIN 1 (cervical intraepithelial neoplasia grade 1) → CIN 2 → CIN 3 → invasive squamous cell carcinoma. CIN 1 represents infection with HPV with mild dysplasia confined to the lower third of the epithelium; approximately 60% of CIN 1 lesions regress spontaneously within 2-3 years due to immune clearance, while 40% persist or progress. CIN 2/3 (collectively termed "high-grade squamous intraepithelial lesion" or HSIL) encompasses moderate to severe dysplasia affecting the lower to middle or full thickness of epithelium without invasion through the basement membrane. These lesions show markedly abnormal mitotic figures, hyperchromatic nuclei with increased nuclear-to-cytoplasmic ratios, and loss of normal epithelial maturation. CIN 2/3 has a natural history of progression to invasive cancer in approximately 30-50% of untreated cases over 10-30 years, making it the critical threshold for intervention. Integration of high-risk HPV DNA, accumulation of additional mutations (particularly in p16, FHIT, E6AP, and telomerase), and immune evasion mechanisms drive progression beyond CIN 3 to invasive carcinoma, where basement membrane invasion and stromal involvement occur.

Persistent HPV infection requires sophisticated immune evasion strategies that prevent clearance and promote chronic infection. High-risk HPV proteins downregulate MHC class I expression on infected epithelial cells, reducing CD8+ T cell recognition of viral antigens. E6 and E7 suppress interferon-α and interferon-β production, limiting innate antiviral responses. The virus induces regulatory T cells (Tregs) through IL-10 and TGF-β signaling, creating an immunosuppressive microenvironment that prevents effective adaptive immunity. This immunologic tolerance is particularly pronounced at the genital mucosa, where tolerogenic dendritic cells predominate. Additionally, HPV-infected cells express programmed death ligand-1 (PD-L1), engaging PD-1 on infiltrating T cells and promoting T cell exhaustion. This explains why infection can persist for years despite the presence of immune cells infiltrating lesions.

Beyond HPV status, accumulation of additional genetic and epigenetic alterations marks progression risk. p16/CDKN2A overexpression occurs as a compensatory response to Rb pathway disruption and serves as a reliable marker of high-grade dysplasia and oncogenic HPV infection. Loss of p53 function through additional mutations (beyond E6-mediated inactivation) and telomerase reactivation (through TERT promoter mutations) facilitate unlimited replicative potential. PIK3CA activating mutations and loss of PTEN enhance proliferation through PI3K/AKT signaling. These molecular alterations correlate with increased progression risk and support the concept of CIN 2/3 as a critical intervention point.

High-risk HPV types (oncogenic HPV), particularly HPV-16 and HPV-18, cause approximately 99% of cervical cancers worldwide. Over 200 HPV types have been identified, but only 14 are classified as high-risk (oncogenic): HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, and -68. HPV-16 alone accounts for approximately 50% of cervical cancers, while HPV-18 accounts for 10-15%, predominantly causing adenocarcinomas. Importantly, persistence of infection is the critical risk factor, not merely transient exposure; 70-90% of sexually active women acquire HPV infection during their lifetime, yet most clear infection within 12-24 months through immune mechanisms. Only women who fail to clear high-risk HPV and develop persistent infection (typically defined as detection of same HPV type at ≥2 visits 6 months apart) progress to precancerous lesions. The median time from initial HPV acquisition to CIN 3 development is approximately 5-10 years, providing a substantial screening window.

Peak HPV acquisition occurs in women in their late teens and early twenties, with incidence declining thereafter in most cohorts. However, a second, smaller peak of acquisition may occur in perimenopause due to increased sexual activity and decreased immune surveillance. Age at first sexual intercourse, number of lifetime sexual partners, and frequency of new partners all correlate with cervical cancer risk through increased HPV exposure probability. Sexual contact with men who have HPV-related genital lesions or who are uncircumcised (associated with higher penile HPV carriage rates) increases transmission risk. Male factor transmission is significant; men with multiple partners and men with penile intraepithelial neoplasia carry higher HPV viral loads.

HIV-positive women (particularly those with CD4+ counts <200 cells/μL) have 3-5 fold increased risk of cervical dysplasia and invasive cancer, with prevalence of high-grade lesions reaching 40% in untreated HIV infection. Prolonged immunosuppression allows persistent HPV replication and reduces the immune clearance that would otherwise eliminate infection. Other states of immunosuppression—including solid organ transplant recipients (5-10 fold increased risk), those on chronic corticosteroids, and those with primary immunodeficiency disorders—similarly elevate risk. The severity of immunosuppression correlates with CIN risk; restoration of immune function with antiretroviral therapy reduces cervical dysplasia progression rates.

Long-term combined oral contraceptive (OCP) use (≥5 years) is associated with 1.5-2.5 fold increased relative risk of cervical cancer, particularly among HPV-infected women. The mechanism remains incompletely understood but may involve progesterone-mediated immunosuppression, altered cervical mucus composition facilitating HPV ascension, or increased epithelial permeability. Critically, this risk does not apply to intrauterine devices (IUDs), which do not elevate cervical cancer risk. The absolute risk increase remains modest given the low baseline cervical cancer incidence in screened populations.

Cigarette smoking increases cervical cancer risk approximately 1.5-2 fold independent of HPV status, with dose-response relationships observed (heavier smokers at greater risk). Tobacco smoke constituents, including benzo[a]pyrene and nitrosamines, are detected in cervical secretions and may directly damage epithelial DNA or impair local immune surveillance through reduced Langerhans cell density and altered T-cell function.

Parity ≥3 pregnancies and age at first full-term pregnancy <20 years independently increase cervical cancer risk, possibly through repeated cervical trauma and altered immunology during pregnancy. The mechanism may also involve selection of cells with higher proliferative capacity during post-partum cervical remodeling.

Diethylstilbestrol (DES) in utero exposure (now historical in developed nations) markedly increases risk, particularly of clear cell adenocarcinoma. Socioeconomic deprivation serves as a proxy for multiple risk factors including reduced screening access, higher HPV prevalence, and increased cofactor exposures. Prior history of sexually transmitted infections (Chlamydia, gonorrhea, genital herpes) associates with increased cervical cancer risk, though whether this reflects causation versus shared risk behavior patterns (increased sexual partners) remains debated. Nutritional deficiencies, particularly of vitamins A, C, and E, have been implicated in cross-sectional studies, though interventional trials of supplementation have not proven protective.

The critical feature distinguishing cervical dysplasia from invasive cervical cancer is that cervical intraepithelial neoplasia produces no symptoms. This asymptomatic nature underlies the entire rationale for screening programs; lesions are detected before they progress to symptomatic invasive disease. Symptoms, when present in patients with cytologic abnormalities, reflect concomitant benign conditions (cervicitis, vaginitis) rather than dysplasia itself.

When abnormal vaginal bleeding occurs in women with cervical dysplasia, it typically indicates progression to invasive cancer rather than dysplasia alone. Postcoital bleeding (bleeding after sexual intercourse) and intermenstrual bleeding result from friable invaded tissue with abnormal vasculature that bleeds with minor trauma. In younger women with abnormal vaginal bleeding, cervical neoplasia must be ruled out even if recent Pap smears were normal, as interval cancers do occur. Postmenopausal bleeding warrants urgent cervical evaluation given the increased invasive cancer risk in this population.

Abnormal vaginal discharge—characterized as purulent, foul-smelling, or blood-tinged—may accompany invasive cervical cancer but is non-specific and more commonly reflects vaginitis or cervicitis. Discharge associated with cervical neoplasia often contains tumor necrosis products and bacterial overgrowth on the necrotic tumor surface. Any unexplained vaginal discharge warrants cervical visualization and assessment.

Pelvic pain, including dyspareunia (pain with intercourse), may indicate advanced cervical cancer with parametrial invasion, pelvic sidewall involvement, or bladder/rectal invasion. Pain is typically a late symptom reflecting locally advanced disease. Referred pain to the flank, lower back, or lower extremities suggests para-aortic lymph node involvement or pelvic sidewall invasion.

Dysuria, urinary frequency, and urinary urgency can result from bladder irritation or involvement by advanced cervical neoplasia. Gross hematuria or hemorrhagic cystitis indicates bladder mucosal invasion. Lower urinary tract symptoms may also reflect concurrent urinary tract infection rather than cervical pathology.

Diarrhea, fecal urgency, and blood in stool indicate rectal involvement by advanced cervical cancer. Constipation may result from external compression of the rectosigmoid by advanced pelvic disease.

Visible cervical lesion: The most specific physical finding is a visible, raised, friable mass on the cervix with irregular borders and areas of ulceration or necrosis. The lesion may appear as an exophytic (outward-growing) fungating mass, an endophytic (inward-growing) ulcerated crater, or an infiltrative lesion causing cervical enlargement and deformity. Any visible cervical lesion warrants immediate biopsy regardless of Pap smear history.

Cervical bleeding: Contact bleeding (bleeding induced by gentle swabbing or speculum manipulation) is highly suggestive of invasive cervical cancer. The bleeding results from neovascular friable tissue with abnormal vasculature and reduced epithelial integrity.

Cervical enlargement or distortion: Advanced cancer may cause cervical hypertrophy, cervical barrel deformity, or cervical fixation (reduced mobility on bimanual exam due to parametrial invasion).

Bimanual examination findings: In advanced disease, parametrial induration or nodularity palpable on lateral cervical stroking indicates stromal invasion. Pelvic sidewall involvement manifests as fixation of the cervix to the pelvic sidewall. Palpable pelvic masses may represent involved lymph nodes. Fixed adnexal masses suggest metastatic involvement.

Patients with extensive metastatic cervical cancer may present with constitutional symptoms including weight loss, fatigue, and anorexia. Leg edema or lymphedema results from pelvic/inguinal lymph node involvement obstructing lymphatic drainage. Abdominal distension may indicate ascites from peritoneal involvement or liver metastases. Respiratory symptoms including cough and dyspnea indicate pulmonary metastases.

The Pap smear (Papanicolaou smear) represents the foundational cervical cancer screening modality that has driven the dramatic reduction in cervical cancer incidence over the past 70 years. Pap smears may be collected using conventional methods (liquid-based cytology now standard in most U.S. centers) or conventional smears. Sensitivity for detecting CIN 2/3 is 80-98%, while specificity is 90-98%, with variation dependent on technique and cytopathology expertise. A single Pap smear has lower sensitivity than repeated screening, emphasizing the importance of regular screening intervals rather than relying on single tests.

Conventional Pap smear results are reported using the Bethesda Classification System (revised 2014), which provides standardized terminology facilitating clinical management: